文献速递流行病学与生物统计新药、器械与细胞基因治疗研发

成人发作性偏头痛的急性治疗:系统综述与Meta分析

Acute Treatments for Episodic Migraine in Adults: A Systematic Review and Meta-analysis.
PubMed 文献 · JAMA · 2021-01-01

曲普坦类、非甾体抗炎药、对乙酰氨基酚、双氢麦角胺、CGRP受体拮抗剂、拉米地坦及部分非药物治疗与疼痛改善相关,阿片类证据有限。

要点

  • 曲普坦类和非甾体抗炎药单用可显著减少2小时和1天疼痛,证据强度中至高级。
  • CGRP受体拮抗剂、拉米地坦、双氢麦角胺、对乙酰氨基酚等与疼痛减轻相关,证据强度不一。
  • 阿片类证据低或不足;远程电神经调控等非药物治疗可改善疼痛且不增加不良事件。

核心结论

  • 多种急性治疗可用于偏头痛,但支持证据强度不一。
  • 曲普坦类、非甾体抗炎药、对乙酰氨基酚、双氢麦角胺、CGRP拮抗剂、拉米地坦及部分非药物治疗与疼痛和功能改善相关。
  • 包括阿片类在内的许多其他干预措施证据有限。

研究设计与样本

  • 系统综述与Meta分析,检索多个数据库自建库至2021年2月24日。
  • 纳入评估偏头痛急性治疗有效性或危害的随机临床试验和系统综述。
  • 采用DerSimonian-Laird随机效应模型(Hartung-Knapp-Sidik-Jonkman方差校正)或Mantel-Haenszel固定效应模型进行Meta分析。
  • 证据强度采用美国医疗保健研究与质量局(AHRQ)方法指南分级。

主要发现

  • 与安慰剂相比,曲普坦类和非甾体抗炎药单用显著减少2小时和1天疼痛(证据强度中至高级),并增加轻度一过性不良事件风险。
  • 与安慰剂相比,CGRP受体拮抗剂(证据强度低至高级)、拉米地坦(5-HT1F受体激动剂;证据强度高级)、双氢麦角胺(中至高级)、麦角胺加咖啡因(中级)、对乙酰氨基酚(中级)、止吐药(低级)、布托啡诺(低级)、曲马多联合对乙酰氨基酚(低级)与疼痛减轻及轻度不良事件增加显著相关。
  • 阿片类药物的发现基于低或不足的证据强度。
  • 多种非药物治疗与疼痛改善显著相关,包括远程电神经调控(中级)、经颅磁刺激(低级)、外部三叉神经刺激(低级)和无创迷走神经刺激(中级)。
  • 非药物治疗与假干预之间未发现不良事件显著差异。

临床怎么用

  • 曲普坦类、非甾体抗炎药、对乙酰氨基酚、双氢麦角胺、CGRP拮抗剂、拉米地坦及部分非药物治疗可用于偏头痛急性治疗以改善疼痛和功能。
  • 阿片类等许多其他干预措施证据有限,临床决策需考虑证据强度。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Migraine is common and can be associated with significant morbidity, and several treatment options exist for acute therapy. OBJECTIVE: To evaluate the benefits and harms associated with acute treatments for episodic migraine in adults. DATA SOURCES: Multiple databases from database inception to February 24, 2021. STUDY SELECTION: Randomized clinical trials and systematic reviews that assessed effectiveness or harms of acute therapy for migraine attacks. DATA EXTRACTION AND SYNTHESIS: Independent reviewers selected studies and extracted data. Meta-analysis was performed with the DerSimonian-Laird random-effects model with Hartung-Knapp-Sidik-Jonkman variance correction or by using a fixed-effect model based on the Mantel-Haenszel method if the number of studies was small. MAIN OUTCOMES AND MEASURES: The main outcomes included pain freedom, pain relief, sustained pain freedom, sustained pain relief, and adverse events. The strength of evidence (SOE) was graded with the Agency for Healthcare Research and Quality Methods Guide for Effectiveness and Comparative Effectiveness Reviews. FINDINGS: Evidence on triptans and nonsteroidal anti-inflammatory drugs was summarized from 15 systematic reviews. For other interventions, 115 randomized clinical trials with 28 803 patients were included. Compared with placebo, triptans and nonsteroidal anti-inflammatory drugs used individually were significantly associated with reduced pain at 2 hours and 1 day (moderate to high SOE) and increased risk of mild and transient adverse events. Compared with placebo, calcitonin gene-related peptide receptor antagonists (low to high SOE), lasmiditan (5-HT1F receptor agonist; high SOE), dihydroergotamine (moderate to high SOE), ergotamine plus caffeine (moderate SOE), acetaminophen (moderate SOE), antiemetics (low SOE), butorphanol (low SOE), and tramadol in combination with acetaminophen (low SOE) were significantly associated with pain reduction and increase in mild adverse events. The findings for opioids were based on low or insufficient SOE. Several nonpharmacologic treatments were significantly associated with improved pain, including remote electrical neuromodulation (moderate SOE), transcranial magnetic stimulation (low SOE), external trigeminal nerve stimulation (low SOE), and noninvasive vagus nerve stimulation (moderate SOE). No significant difference in adverse events was found between nonpharmacologic treatments and sham. CONCLUSIONS AND RELEVANCE: There are several acute treatments for migraine, with varying strength of supporting evidence. Use of triptans, nonsteroidal anti-inflammatory drugs, acetaminophen, dihydroergotamine, calcitonin gene-related peptide antagonists, lasmiditan, and some nonpharmacologic treatments was associated with improved pain and function. The evidence for many other interventions, including opioids, was limited.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. VanderPluym JH, Halker Singh RB, Urtecho M, et al. Acute Treatments for Episodic Migraine in Adults: A Systematic Review and Meta-analysis. JAMA. 2021. PMID: 34128998. doi:10.1001/jama.2021.7939

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。